Biological characteristics of a new human glioma cell line transformed into A2B5+ stem cells
- Yanyan Li†1,
- Hangzhou Wang†1,
- Ting Sun1,
- Jinming Chen1,
- Lingchuan Guo2,
- Haitao Shen1,
- Ziwei Du1 and
- Youxin Zhou1Email author
© Li et al.; licensee BioMed Central. 2015
Received: 26 November 2014
Accepted: 13 March 2015
Published: 2 April 2015
The new glioma cell line SHG-139 was established and its phenotype, tumorigenicity, pathological characteristics, derived stem cells SHG139S were studied.
Immunohistochemistry was used to assess expressions in the patient and mouse tumor tissues, SHG-139 and SHG-139S. Primary SHG-139 culture was performed, cell proliferation, cell cycle and genetic characteristics were assessed. MiRNA (Micro RNA) and LncRNA (Long non-coding RNA) microarray was performed.
We found that the glioma tissue was positive for A2B5 (Glial precursors ganglioside), GFAP (Glial fibrillary acidic protein), S-100 (Acid calcium bingding protein), VEGF (Vascular endothelial growth factor), VEGFR (Vascular endothelial growth factor receptor) and negative for Ki-67 (Nuclcar- associated antigen). SHG-139 proliferated significantly within 24h; its total number of chromosomes was 68; ratios of SHG-139 and SHG-139S cells in G1 phase were highest. SHG-139 cells were positive for A2B5, GalC (Galactocerebrosides), GFAP, S-100 and Vimentin, while SHG-139S cells were positive for A2B5, Nestin, and NG2 (Neuron-glia antigen2), and negative for Vimentin and IDHR132H (Isocitrate dehydrogenase); cells rarely stained for CD133 (Cluster of differentiation133). SHG-139 intracranial xenografts expressed GFAP, but no overt oligodendroglioma was observed. In SHG-139S xenografts, GFAP and S-100 were expressed, while CD133 was not detected; a few A2B5+ cells were found at tumor edges, and typical oligodendroglioma were obtained. In addition, SHG-139S xenograft tumors were more aggressive than those of SHG-139. Anti-mouse CD31 (Cluster of differentiation31) staining revealed murine vessels at the border between xenograft tumor and normal brain tissue; Anti-human CD34 (Cluster of differentiation34) staining was negative. Biochip technology of SHG139S showed several miRNA and lncRNA were differently expressed in SHG139 and SHG139S.
SHG-139 was an astroglioma cell line which yielded stem cells SHG-139S. SHG-139S cells constituted an A2B5+/CD133− GSC subgroup.
Glioma is the most common intracranial malignancy in adults, and is associated with poor outcomes. Emerging evidence suggests there is a rare population of tumor cells, called glioma stem cells (GSCs), which are responsible for glioma initiation, propagation, resistance to radiotherapy and recurrence of disease . We previously established the first human glioma cell line SHG-44 in china , which has positively impacted glioma research in our country. To further characterize glioma, this study established a glioma cell line, which can transform into glioma stem like cells with A2B5+. This cell line were obtained from surgical resection of brain tumor tissue of a 23-year-old male patient (database specimen No. 139, SHG-139), so this cell line was named SHG139. The patient’s clinical diagnosis was WHO II grade fibrous astrocytoma. Although there are many cell lines from GBM (Glioblastoma multiforme), permanent lines from low grade glioma have rarely been established, therefore, this cell line will fill the gap in low grade glioma biological and clinical studies. Molecular biological characteristics of the cell line, pathological and histological characteristics of intracranial and subcutaneous tumor patterns related this cell line will be detailed in this work.
Primary culture of SHG-139 cells and their molecular characteristics
SHG-139 cells were passaged to the 60th generation, and tumor cells were adherent, and showed irregular nuclei clearly demarcated and significant cell protrusions, was similar to SHG-139 in the 20th generation. Immunofluorescence staining of glioma cells (60th generation), assessed by laser confocal microscopy, revealed the presence of IDH1R132H, A2B5, GalC, Vimentin, GFAP, and S-100 (Figure 2, B1-B6).
Molecular characteristics of SHG-139S and its differentiated cells cultured in DMEM/F12 with fetal bovine serum
Glioma stem like cell spheres of the 10th generation were assessed by immunofluorescence, 4.2 ± 1.29% SHG-139S cells in spheres were CD133+ (Figure 2, C1) and 84.12 ± 9.96% cells stained positive for A2B5 (Figure 2, C2). SHG-139S were confirmed as A2B5+ /CD133− GSC (Glioma stem cells) subset. Next, the expression of different glioma molecular markers in different GSC subsets of SHG-139S were analyzed. In A2B5+ /CD133− SHG-139S glioma stem like cell spheres, the percentages of positive cells for IDH1R132H (Figure 2, C1), Nestin (Figure 2, C3), NG2 (Figure 2, C4) and Vimentin (Figure 2, C5) were respectively 36.77 ± 13.19%,73.86 ± 5.01%, 49.12 ± 12.83% and 73.37 ± 2.09%.
Cells in the 20th generation were cultured in NSCM (neural stem cell medium), and glioma stem like cell spheres were formed after 1 week in suspension, but there was still a large number of adherent cells (Figure 1, B). When passaging, only suspended cell spheres were collected and the adherent ones discarded. Until the 10th generation, a large number of glioma stem like cell spheres were observed in suspension, with only few adherent cells. These cells were named SHG-139S (Figure 1, C). SHG139S was cultured in DMEM/F12 medium without bFGF (basic fibroblast growth factor) and EGF (epidermal growth factor) and containing 10% fetal bovine serum, cells were adherent after 6h, with more adherent cells among spheres; almost all cells were adherent after two days (Figure 1, D-F).
Cell proliferation and chromosome karyotype of SHG-139 cells
Clinical radiological and pathological data of the patient
Pathological analysis and immunohistochemistry of SHG-139 and SHG-139S subcutaneous xenografts
Subcutaneous xenografts of SHG-139 and SHG-139S were compared. subcutaneous model of SHG-139 had obvious boundary, tumor cells had a high density, with spindle-, circular- and other irregular shape and displayed overt nuclear atypia ((Figure 5, B1-B2). Immunohistochemistry of tumor was positive for GFAP and A2B5, however, obvious oligodendroglioma components were not found in this tumor model (Figure 5, B3-B4).
Intracranial SHG-139S xenografts showed invasive growth, with no obvious boundary (Figure 5, C1); tumor cells also had a high density, with spindle-, circular- and other irregular shape. Cells displayed overt nuclear atypia, with rare megakaryocytes observed and pronounced nuclear mitosis, and low degree of differentiation (Figure 5, C2). Microvascular hyperplasia was visible in some areas, with no significant vascular thrombosis and false fence necrosis changes. Oligodendroglioma ingredients featured with typical “honeycomb” and “fried egg-like” structures were identified (Figure 5, C3).
Immunohistochemical staining revealed low ratio of A2B5+ tumor cells, suggesting that the majority of SHG-139S glioma stem like cells expressing A2B5+ differentiated in vivo (Figure 5, D1). Meanwhile, A2B5+ cells were found at the edge, in a cord-like distribution, with no obvious continuity with xenograft tumor cells, indicating their aggressiveness (Figure 5, D2). A little expression of CD133 was detected in xenograft tumor (Figure 5, D3), GFAP and S-100 were detected (Figure 5, D4, D6). Interestingly, GFAP and S-100 expression was detected in oligodendroglioma ingredients of the tumor (Figure 5, D5, D7). CD31 staining showed that murine tumor blood vessels were located in the junction between the xenograft and normal brain tissue (Figure 5, D8). Indeed, xenograft tumor cells invaded outward along murine blood vessels; immunohistochemical staining with anti-human CD34 antibody yielded no signals (Figure 5, D9).
Variant miRNA and lncRNA heatmap between SHG139 and SHG139S
Cell culture is one of the most powerful tools in cancer research, with 60 years of history so far . The earliest glioma cell lines cultured were rat glioma C6 and 9L, and human glioma U251 and U87 [4-6]. Professor Ziwei Du generated the first glioma cell line SHG-44 in our laboratory in 1984. The glioma cell line SHG-139 studied herein was gained successfully in serum-containing RPMI 1640 from WHO II grade astrocytoma (fiber type), and can be stably passaged. SHG139 in the 20th and 60th generations had the same molecular markers and cell morphology: GFAP, S-100 and Vimentin were expressed, and tumor cells were diploid or polyploid. Immunohistochemistry of tumor specimens showed the expression of A2B5, GFAP, S-100, VEGF and VEGFR, while Ki-67 was not detected.
Recent studies have shown that brain cancer evolves from a specific tumorigenic cell subset with highly self-renewal potential called tumor or cancer stem cells . There are many culture methods for glioma stem cells: flow cytometry for molecular markers and immuno-magnetic beads are most commonly used; other methods include separation of side population (SP) cells and auto-Fluorescence [8-11]. Under NSCM with bFGF and EGF, N2 and without serum, GSCs were obtained from human glioma primary cultures or glioma cell lines, maintained parental tumor molecular phenotype, and even kept parental genotype [12-14]. This method is also known as sphere forming method; GSCs grow in the culture as suspension since they are neural stem cells (NSC) [15,16]. The new glioma cell line showed stable passage characteristics, and experimental reproducibility was good. GSCs have been gained from cell lines under NSCM in a number of studies, and the use of these GSCs has contributed significantly to reveal therapeutic targets for glioma [17-20].
In this study, SHG-139S glioma stem cell spheres were acquired from SHG-139 glioma cells under NSCM, and sphere formation rate was high. Many studies have shown that sphere formation rate of glioma stem cells is closely related with patient prognosis [21,22]. Interestingly, decreased numbers of G1 phase cells were observed in SHG-139S, while the rate of G2 phase cells was increased, compared with the values obtained for SHG-139 cells; these differences were likely related to the effects of bFGF and EGF on tumor cells. Indeed, EGF and bFGF were shown to play important roles in the development of NSC and nervous system, and self-renewal of GSCs was also closely related to EGF and bFGF [23-25].
Immunofluorescence indicated no expression of CD133, while A2B5 was detected in SHG-139s. CD133 is a well-known GSC surface marker; however, glioma stem cells with CD133− have been identified . Secondary sphere formation assay confirmed that SHG-139S have self-renewal capacity; immunofluorescence confirmed the expression of Vimentin in cells with the neural stem cell marker Nestin+; when SHG-139S were induced to differentiate in NSCM containing serum and without bFGF and EGF, adherent cells were observed, and GFAP, the early neuronal marker β-III Tubulin and the oligodendroglioma marker GalC were expressed. A2B5 was also previously confirmed as glioma stem cell marker [27,28].
With the development of GSC culture technology, GSCs with parent tumor genetics, genotype characteristics and heterogeneity characteristics in NSCM without serum, its xenograft has an advantage in affinity . SHG-139S cells with A2B5 +/CD133−were obtained in NSCM and its pathological model was established. As shown above, SHG-139 orthotopic xenograft were low invasive, but SHG-139S orthotopic xenograft model in nude mice reflected the high invasive type of GSCs. Two distinct tumor histological types in SHG139S xenograft were visible: one type was composed of irregularly shaped cells, and was similar to glial cell sarcomatoid changes; the other type showed oligodendroglioma changes and was composed of relative regular “fried egg-like” shape cells. Immunohistochemical staining of GFAP and S-100 was positive in both pathological types. The specific pathology may be associated with characteristics of GSCs (A2B5+/CD133−).
A2B5 are markers of oligodendroglioma-II astrocytes progenitors (O-2A progenitors). From the perspective of differentiation lineage, O-2A progenitor cells differentiate into oligodendroglioma or type II astrocytes cells, but it has been shown that these cells cannot differentiate into the latter, and are therefore mostly named as oligodendrocyte precursor cells (OPCs) . It was proposed that oligodendroglioma tumor is formed by GSCs with A2B5 phenotype, which determines their further differentiation outcome. Meanwhile, immunohistochemistry of A2B5 in SHG-139S xenografts suggested that GSCs with A2B5+ differentiated in vivo and mostly lost the A2B5 molecular phenotype. Indeed, tumor cells with A2B5+ were arranged in cord-like distribution at the outer edge of the tumor, indicating their aggressiveness. In this xenograft model, anti-human CD34+ tumor cells were not found; anti-mouse CD31 staining showed murine tumor blood vessels at the edge of the xenograft, rarely in the center; anti-mouse CD34 staining revealed that murine tumor blood vessels outside the xenograft were surrounded by a high density of tumor cells, suggesting that SHG-139S cells invade outside along murine vascular system. Although SHG-139S cells with A2B5+/CD133−appeared with morphological changes similar to vascular mimicry in DMEM/F12 medium without EGF, bFGF and containing fetal bovine serum, this was not observed in vivo, suggesting that these GSCs were not closely related to formation of vascular mimicry.
Gene microarray was used to study SHG-139S and its parent cell line SHG-139, and some miRNAs and lncRNAs were different in two cells. Further experiments are underway in our group to unveil the effects of the different miRNAs and LncRNAs identified on glioma.
In conclusion, much attention should be paid on heterogeneity of glioma in order to solve current problems of chemotherapy and further targeted therapy. Comprehensive understanding of glioma cell pathology is one of the most promising ways to overcome the disease. Improvements of glioma cell culture technology, optimization of glioma model, progress of biochemical research tools, intelligence of bioinformatics, and multi-level comprehensive research tool will bring new breakthrough for basic research and clinical treatment of cancers.
Materials and methods
Clinical sampling and experimental animals
Glioma tissue sample was obtained from a patient at the department of neurosurgery in the First Affiliated Hospital of Soochow University in 2010. This study was approved by the ethics committee of Soochow University. The tissue in glioma sample library of our laboratory was registered as Suzhou human glioma NO: 139, so was named SHG–139. Nerve tumors’ standard of WHO in 2007 was used for diagnosis and tumor was taken out in sterile condition and packed into a sterile culture bottle and formaldehyde solution; a portion of the sample was frozen in liquid nitrogen. Twenty BALB/C nude mice were purchased from the institute of model animals of Nanjing University and housed in SPF nude mouse room of our laboratory.
Primary cell culture and subculture of human glioma
Fresh glioma sample was washed and minced in PBS (1×) followed by 0.25% enzymatic dissociation at 37°C for 20 min. The isolated cells were resuspended in RPMI 1640 supplemented with 2 mM L-glutamine, 1% Penicilin–Streptomycin and 10% Fetal Bovine Serum (GIBCO, Invitrogen Corporation, USA). Next, cells were seeded in 25 cm2 culture flasks and maintained in a humidified incubator (Thermo Fisher Scientific Inc.3110, Waltham, MA, USA) with 5% CO2 at 37°C, with the culture medium replaced every other day. When cells reached 80% confluency, they were passaged after 0.25% trypsin digestion. Single cell clone was performed at the tenth generation and a stable passage cell line SHG139 was gained and authenticated successfully (Additional file 1: Table S1 and Additional file 2: Figure S1).
Immunofluorescence assay of SHG-139 and SHG-139S
Microslides were treated with poly-L-lysine, sterile rinsed with water, UV sterilized, and dried. Single cell suspensions or sphere cell suspensions were dropped on glass slides. After fixation at room temperature with 4% paraformaldehyde, cells were blocked with goat serum and permeabilized with 0.1% Triton X-100. Primary antibodies A2B5 (mouse anti-human IgM), GC (rabbit anti-human IgG), Vimentin (mouse anti-human IgM), GFAP (mouse anti-human IgM) and S-100 (mouse anti-human IgG) were added and incubated overnight at 4°C. Cells were rinsed with PBS, and fluorescence-labeled secondary antibodies were added and incubated at room temperature, protected from light for 1h. Then cells were counterstained with DAPI for 1 min, rinsed with PBS and sealed with mounting medium. The slides were respectively analyzed by fluorescence microscopy (Olympus, Japan), confocal microscopy (Leica, German) and optical microscopy (Olympus, Japan).
SHG-139 was transformed into glioma stem cells SHG139S and SHG139S was induced to adherent cells
SHG-139 cells of the 20th generation were seeded into 6-well plates at a density of 1000 cells/well in neural stem medium composed of DMEM/F12 (Gibco, USA), 20 ng/mL EGF (Invitrogen, USA), 20 ng/mL bFGF (Invitrogen), 1% N2 (Gibco) and 1% Penicilin–Streptomycin. Cells were cultured at 37°C with 5% CO2, and cell growth was assessed under an inverted phase contrast microscope. Glioma stem cell spheres grew as suspension, and half of the culture medium was replaced for passaging. Glioma stem cells grown in suspension spheres were gently drawn when passaging, and cultured. Glioma cells derived from SHG-139 were named SHG-139S. To induce differentiation of SHG-139S spheres, they were cultured in DMEM/F12 medium contained 10% fetal bovine serum, without bFGF, EGF and other growth factors.
Determination of glioma cell proliferation
2 × 103 cells were seeded in 96-well plates and cultured in medium with 10% fetal bovine serum. A total of 6 groups were set: 0h, 24h, 48h, 72h, 96h, and 120h, each time point had three replicates. At each time point, cells in a well were treated with MTT solution (5 mg/ml in PBS) 20ul, and incubated for 4h, supernatant medium was discarded, added with 150 ul DMSO (dimethylsulfoxide), vibrated for 10 min. Cells were measured at 570 nm wavelength.
Genetic analysis of glioma
SHG-139 cells of the 20th generation were cultured for four days. After treatment with colchicine (25 μg/ml) for 6 h, preheated 0.075 mM Kcl was added for 30 min at 37°C. Then, fresh stationary liquid (methanol: glacial acetic acid =3:1) was added and cells were centrifuged at 1200 rpm for 10 min. The pellets were fixed at room temperature for 10 min (4 times), and 500 μl stationary liquid was added to resuspend the cells. Afterward, cell droplets were applied to clean microslides that had been soaked in 4 to 6°C ice water. The samples were baked in 80°C constant temperature drying oven for 15 min. After Giemsa staining, the microslides were assessed by optical microscopy.
Pathological examination and immunohistochemistry of the patient glioma tissue
The tissue was fixed in 10% formalin, dehydrated with ethanol gradient, permeabilized with xylene and paraffin embedded. Then, serial 5 μm thick sections were cut, deparaffinized with xylene, hydrated with ethanol gradient and stained with hematoxylin and eosin (H & E) (Sigma-Aldrich, USA). Meanwhile, immunohistochemical staining was performed for A2B5, GFAP, VEGFR, S-100, VEGF, and Ki-67 detection. Endogenous peroxidase inactivation was carried out with 3% H2O2, and antigen retrieval was performed in a microwave. Afterward, primary antibodies were added to each slide at appropriate dilutions, and the sections incubated with biotin-labeled secondary antibodies for 10 min. The final signals were developed using the 3,3’-diaminobenzidine substrate (DAB) (RD, America), The sections were analyzed by optical microscopy after counterstaining with hematoxylin.
Pathological analysis and immunohistochemistry of mouse xenograft tumor model
Glioma cells and stem cells were counted, resuspended to 1 × 105 cells/μL, implanted in the right side of the brain caudate nucleus of BALB/c nude mice (n = 5). The whole process was completed in our nude SPF level room. Nude mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital, positioned on a stereotactic apparatus with prone position, and the head fixed. After alcohol disinfection of the skin of the top head, a 0.5-1.0 cm longitudinal incision was made on the frontal, 3.5 mm from cerebral midline, 2 mm frontal to coronal seam. Then the skull was carefully drilled with a dental drill. Micro-injector with10 μL tumor cell suspension was fixed on the stereotactic apparatus, and inserted vertically into brain parenchyma. The depth of the needle tip was adjusted to 3 mm from cerebral surface, and the tumor cell suspension was injected automatically for 5 min. We observed the status of nude mice with tumor after injection, including neurological deficits. Survival times were recorded and mice were sacrificed when they developed cachexia. Upon sacrifice, the whole brain tissue was removed and fixed in formalin. Pathological analysis and immunohistochemistry of A2B5, CD133 (mouse anti-human IgG), GFAP, S-100, CD31 (rabbit anti-mouse IgG), CD34 (mouse anti-human IgG) of mouse xenograft tumors were performed.
MiRNA and lncRNA microarray analysis
Total RNA was extracted using the TRIZOL Reagent (Life technologies, Carlsbad, CA, US), and assessed for amounts and integrity on an Agilent Bioanalyzer 2100. RNA samples were further purified by RNeasy mini kit (QIAGEN, GmBH, Germany) and RNase-Free DNase Set (QIAGEN, GmBH, Germany).
MiRNA were labeled by the labeling section of miRNA Complete Labeling and Hyb Kit (Agilent technologies, Santa Clara, CA, US). Each slide was hybridized with 100 ng Cy3-labeled RNA using the hybridization section of miRNA Complete Labeling and Hyb Kit (Agilent technologies, Santa Clara, CA, US) in hybridization Oven (Agilent technologies, Santa Clara, CA, US) at 55°C, 20 rpm for 20 hours. After hybridization, slides were washed in staining dishes (Thermo Shandon, Waltham, MA, US) with the Gene Expression Wash Buffer Kit (Agilent technologies, Santa Clara, CA, US). After hybridization, slides were scanned by Agilent Microarray Scanner (Agilent technologies, Santa Clara, CA, US) with default settings, Scan resolution = 5μm, PMT 100%, 5%. Data were extracted by feature Extraction software 10.7 (Agilent technologies, Santa Clara, CA, US), and normalized by Quantile algorithm, Gene Spring Software 11.0 (Agilent technologies, Santa Clara, CA, US).
Total RNA was amplified and labeled with the Low Input Quick Amp Labeling Kit, One-Color (Agilent technologies, Santa Clara, CA, US). Labeled cRNA was purified by RNeasy mini kit (QIAGEN, GmBH, Germany). Each Slide was hybridized with 1.65 μg Cy3-labeled cRNA using the Gene Expression Hybridization Kit (Agilent technologies, Santa Clara, CA, US) in Hybridization Oven. After 17 hours hybridization, slides were washed in staining dishes with the Gene Expression Wash Buffer Kit. Slides were scanned on Agilent Microarray Scanner with default settings: Dye channel, Green; Scan resolution = 3 μm, 20 bit. Data extraction and normalization was carried out as described for miRNAs.
We thank the Animal Research Institute in Nanjing University for providing nude mice. We thank our central lab for providing technical instruction and assistance. Finally, we thank Shanghai Biotechnology Corporation for providing experimental support and data analyse of Gene chip. This work was supported by grants from the National Science Foundation entitled: “Experimental study on the mechanism of candidate lncRNA regulating stemness maintenance and invasion of A2B5+/CD133−glioma stem cells” (NO.81372689).
- Yan GN, Yang L, Lv YF, Shi Y, Shen LL, Yao XH, et al. Endothelial cells promote stem-like phenotype of glioma cells through activating hedgehog pathway [J]. J Pathol. 2014;3:6.Google Scholar
- Wu TF, Chen JM, Chen SS, Chen GL, Wei YX, Xie XS, et al. Phenotype of SHG-44 glioma stem cell spheres and pathological characteristics of their xenograft tumors [J]. Zhonghua Zhong Liu Za Zhi. 2013;35(10):726–31.PubMedGoogle Scholar
- Gangoso E, Thirant C, Chneiweiss H, Medina JM, Tabernero A. A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype [J]. Cell Death Dis. 2014;5:e1023.View ArticlePubMed CentralPubMedGoogle Scholar
- Auf G, Jabouille A, Delugin M, Guérit S, Pineau R, North S, et al. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.[J]. BMC Cancer. 2013;13:597.View ArticlePubMed CentralPubMedGoogle Scholar
- Henderson SD, Kimler BF, Morantz RA. Radiation therapy of 9L rat brain tumors [J]. Int J Radiat Oncol Biol Phys. 1981;7:497–502.View ArticlePubMedGoogle Scholar
- Ponten J. Neoplastic human glia cells in culture [M]. In: Human Tumor Cells in vitro [J]. New York: Plenum Press; 1975. p. 175–85.View ArticleGoogle Scholar
- Pavon LF, Marti LC, Sibov TT, Malheiros SM, Brandt RA, Cavalheiro S. Gamarra. In vitro analysis of neurospheres derived from glioblastoma primary culture: a novel methodology paradigm [J]. Front Neurol. 2014;4:214.View ArticlePubMed CentralPubMedGoogle Scholar
- Fukaya R, Ohta S, Yamaguchi M, Fujii H, Kawakami Y, Kawase T, et al. Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1 [J]. Cancer Lett. 2010;291:150–7.View ArticlePubMedGoogle Scholar
- Dou J, Gu N. Emerging strategies for the identification and targeting of cancer stem cells [J]. Tumour Biol. 2010;31:243–53.View ArticlePubMedGoogle Scholar
- Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies [J]. J Cell Biochem. 2009;108:1031–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Clément V, Marino D, Cudalbu C, Hamou MF, Mlynarik V, de Tribolet N, et al. Marker-independent identification of glioma-initiating cells [J]. Nat Methods. 2010;7:224–8.View ArticlePubMedGoogle Scholar
- Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines [J]. Cancer Cell. 2006;9:391–403.View ArticlePubMedGoogle Scholar
- Fael Al-Mayhani TM, Ball SL, Zhao JW, Fawcett J, Ichimura K, Collins PV, et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours [J]. J Neurosci Methods. 2009;176:192–9.View ArticlePubMedGoogle Scholar
- Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, et al. CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors [J]. BMC Cancer. 2010;10:66.View ArticlePubMed CentralPubMedGoogle Scholar
- Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells [J]. Cell Stem Cell. 2011;8:486–98.View ArticlePubMed CentralPubMedGoogle Scholar
- Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA, et al. Multicellular tumor spheroids: an underestimated tool is catching up again [J]. J Biotechnol. 2010;148:3–15.View ArticlePubMedGoogle Scholar
- Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J, et al. Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets [J]. Exp Cell Res. 2008;314:2110–22.View ArticlePubMed CentralPubMedGoogle Scholar
- Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P, et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells [J]. Stem Cells. 2007;25:1645–53.View ArticlePubMedGoogle Scholar
- Wu A, Oh S, Wiesner SM, Ericson K, Chen L, Hall WA, et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties [J]. Stem Cells Dev. 2008;17:173–84.View ArticlePubMedGoogle Scholar
- Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in many cancer cell lines [J]. Cell Cycle. 2004;3:414–5.View ArticlePubMedGoogle Scholar
- Thirant C, Bessette B, Varlet P, Puget S, Cadusseau J, Tavares Sdos R, et al. Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors [J]. PLoS One. 2011;6:e16375.View ArticlePubMed CentralPubMedGoogle Scholar
- Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma [J]. Stem Cells. 2009;27:980–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens [J]. Stem Cells. 2009;27:1722–33.View ArticlePubMedGoogle Scholar
- Gremo F, Presta M. Role of fibroblast growth factor-2 in human brain: a focus on development [J]. Int J Dev Neurosci. 2000;18:271–9.View ArticlePubMedGoogle Scholar
- Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells [J]. J Biol Chem. 2008;283:10958–66.View ArticlePubMedGoogle Scholar
- Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions [J]. Cell Death Dis. 2011;2:e200.View ArticlePubMed CentralPubMedGoogle Scholar
- Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, et al. Identification of A2B5 + CD133- tumor-initiating cells in adult human gliomas [J]. Neurosurgery. 2008;62:505–14. discussion 514–505.View ArticlePubMedGoogle Scholar
- Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties [J]. Brain Pathol. 2010;20:211–21.View ArticlePubMedGoogle Scholar
- Vik-Mo EO, Sandberg C, Olstorn H, Varghese M, Brandal P, Ramm-Pettersen J, et al. Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions [J]. Neuro Oncol. 2010;12:1220–30.PubMed CentralPubMedGoogle Scholar
- Chandran S, Hunt D, Joannides A, Zhao C, Compston A, Franklin RJ. Myelin repair: the role of stem and precursor cells in multiple sclerosis [J]. Philos Trans R Soc Lond B Biol Sci. 2008;363:171–83.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.